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The tumor suppressor APC is mutated in 85% of colon cancer cases.  APC is 
necessary for normal colon homeostasis, and loss of APC function is the initiating event 
in colon cancer.  APC is a FUXFLDOPHPEHURIWKHȕ-catenin destruction complex, and it 
was long thought APC mutation causes disruption of this complex, removing the cell’s 
DELOLW\WRGHVWUR\H[FHVVȕ-catenin DQGDFWLYDWLQJȕ-catenin/Tcf/Lef-induced transcription.
Recent studies, however, show that nuclear localization of ȕ-catenin occurs only after the 
activation of k-ras, not during the initiation of tumorigenesis.  Thus, APC must play
additional roles that are disrupted when mutated to cause changes from normal colon 
homeostasis.
In this dissertation, we utilize the apcmcr mutant zebrafish as a model to parallel 
the loss of APC in colon cancer to show that multiple epigenetic aberrations occur before 
WKHDGYHQWRIQXFOHDUȕ-catenin, showing that dysregulation of epigenetic marks correlates 
with the initiation of colon cancer progression.  The data presented in this dissertation 
identify two epigenetic factors regulated by APC.  We show that the histone demethylase 
LSD1 aberrantly represses retinoid biosynthesis, preventing terminal differentiation of 
the intestine.  This highlights one of the epigenetic regulators that is misregulated when
APC is lost and adds an epigenetic mechanism for the repression of rdh1l.
We also show that in the apcmcr mutant zebrafish, retinoic acid loss causes 
decreased H3K27 methylation levels, adding another layer of epigenetic regulation 
iv
controlled through RA.  In this case, we uncover an epistatic mechanism wherein Cox-2
regulates H3K27 methylation, LQGHSHQGHQWRILWVUROHLQWKHUHJXODWLRQRIȕ-catenin, when 
APC is mutated.
We also used the developing zebrafish as a model to characterize the loss of the 
Ezh2, the histone methyltransferase responsible for H3K27 methylation.  We show that 
loss of Ezh2 leads to several development phenotypes, including the loss of terminal 
differentiation of multiple cell types in the gut. 
Together, the data presented in this dissertation trace the epigenetic pathways 
used to both regulate retinoic acid production and used by retinoic acid to promote 
cellular differentiation and establish APC as a regulator of histone methylation during 
differentiation.
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1.1 Regulation of Intestinal Differentiation 
Four types of terminally differentiated cells exist within the intestine: absorptive 
enterocytes (also called columnar cells), Paneth cells, goblet cells and enteroendocrine 
cells (1).  (Differentiated zebrafish intestines lack Paneth cells but retain the other three 
cell types (2).)  Absorptive enterocytes are the most abundant cell type in the intestine.  
Enterocytes functions to absorb dietary nutrients.  Goblet cells are responsible for the 
secretion of mucus into the intestinal lumen.  Enteroendocrine cells account for less than 
1% of differentiated intestinal cells and, like goblet and Paneth cells, are secretory, but 
enteroendocrine cells secrete intestinal hormones.  Paneth cells reside at the base of the 
crypt and secrete lysozymes and other microbicidal agents (3). 
As the adult intestine turns over every 3 to 5 days, these cells are being constantly 
replaced (4).  Stem cells reside at the bottom of a crypt and have the capability to give 
rise to all differentiated cell types.  To retain integrity, stem cells divide and produce one 
new daughter stem cell and one transit-amplifying cell, a rapidly dividing intermediate.  
As the transit-amplifying cell travels up the crypt, it will divide in order to provide cells 
for repopulation.  Some estimates have the transit-amplifying cells undergoing six rounds 
of cell division, producing up to 300 cells per crypt each day (5).  Upon leaving the 
rapidly dividing zone, these cells will differentiate into one of the differentiated cell types
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(1, 4).  (Transit-amplifying cells destined to become Paneth cells will travel downward to 
the bottom of the crypt.)  This process takes approximately 3–5 days. 
The loss of retinoic acid signaling disrupts this process, causing loss of terminal 
differentiation in the zebrafish intestine (6). Although addition of exogenous retinoic acid 
is sufficient to restore intestinal differentiation, it is not currently known whether RA 
plays a role in the transition from transit-amplifying cells into differentiated cell types or 
whether RA functions to create and prime the transit-amplifying cell upon asymmetric 
stem cell division.   
 In addition to RA, several other pathways are involved in the repopulation of 
intestinal structures.  Indian hedgehog (Ihh) is expressed in the intervillus region and may 
regulate stem cell renewal and differentiation (7–10). Ihh also regulates BMP production, 
which plays a role in the restriction of crypt numbers (7, 12, 13).  Notch signaling has 
also been implicated in controlling differentiation of intestinal cells and specifically in the 
absorptive cell differentiation (14–16).  Notch signaling may also be necessary for the 
maintenance of putative intestinal stem cells (17).  Activation of canonical Wnt signaling 
has been shown to be necessary for the presence of secretory cells, and overexpression of 
the Wnt inhibitor Dkk-1 appears in some conditions to lead to reduced cell proliferation 
(18, 19).  The transcription factor Tcf4 is thought to be the main effector of the canonical 
Wnt signaling pathway in the gut, and Tcf4 knockout mice die shortly after birth and lose 
the transit-amplifying cells of the intestine (18). 
 
1.2. Colon Cancer and the Adenomatous Polyposis Coli Protein 
 
Colorectal cancer is the third most diagnosed cancer in the U.S. annually, with an 
estimated 137,000 cases to be diagnosed in 2014.  It kills about 50,000 men and women 
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annually, making it the third leading cause of cancer death (20).  While several inherited 
syndromes can give rise to colorectal cancer (most notably FAP (21), Lynch Syndrome 
(22), and MUTYH-associated polyposis (23, 24)), these only account for 2–5% of all 
colorectal cancer cases (25).  The vast majority of colorectal cancer cases are sporadic 
with no family history.  Approximately 85% of colon cancers harbor a mutation in the 
tumor suppressor gene adenomatous polyposis coli, or APC (26, 27).  This gene is 
mutated in the autosomal dominant FAP syndrome (28, 29).  Carriers inherit one mutated 
copy of APC, and cells within the intestine undergo either loss of heterozygosity or a 
second mutation, giving rise to adenomatous polyps containing two mutated copies of 
APC.  These patients will develop hundreds to thousands of these polyps in the colon and 
most will have prophylactic colectomies by age 40 in order to prevent colon cancer (30). 
 APC is a 312 kDa protein that contains multiple domains for interaction (31) 
(Figure 1.1).  It acts within numerous cellular processes and is most well known for its 
role in the canonical Wnt signaling pathway, which is discussed below.  It also 
participates in cell adhesion, cell migration, and chromosomal segregation.  APC contains 
the Armadillo repeats, domains for binding Axin1 (SAMP repeats), the basic region, a 
poorly defined region responsible for interaction with microtubules, and the EB1-binding 
and DLG-binding domains (32–36).  The c-terminal region also binds to the C-terminal 
binding protein, a transcriptional corepressor (37). APC contains multiple 15- and 20-
amino acid repeats, responsible for binding β-catenin (28, 36, 38).  The majority of APC 
mutations occur within a 227-amino acid region known as the mutation cluster region 
(MCR) (39, 40), and 95% of APC mutations lead to C-terminal truncations (41).  This 
eliminates multiple interaction domains, including the regions that bind to Axin and CtBP 
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(42).  A C-terminal mutation in the MCR does, however, leave intact all of the 15-amino 
acid repeats, capable of binding β-catenin. 
 APC interacts with several other proteins to form the β-catenin destruction 
complex (Figure 1.2).  The other core members of this complex include Axin1, the 
serine-threonine kinase GSK3β, and Casein Kinase 1 (CK1) (43, 44).  In the absence of 
Wnt ligand, GSK3β and CK1 phosphorylate one threonine and three serine residues in 
the amino-terminal portion of β-catenin.  This allows for recognition of β-catenin by an 
E3 ubiquitin-ligase, which leads to ubiquitination of β-catenin and subsequent 
degradation by the proteasome.  The Wnt signaling pathway is activated when a Wnt 
ligand binds to a frizzled receptor and an LRP coreceptor on the cell surface.  This 
activates a downstream signaling cascades that results in disintegration of the β-catenin 
destruction complex and accumulation of β-catenin (45).  It is, however, important to 
note that β-catenin cannot enter the nucleus until additional phosphorylation events 
happen at serine 191 and serine 605, which are catalyzed by Rac1 (46, 47).   
 APC mutation is the initiating event in colon cancer (48, 49).  It is this mutation 
that drives the conversion from normal epithelium to hyperplastic epithelium, which then 
propels the cell toward becoming adenomatous and eventually tumorigenic (Figure 1.3).  
It has long been held that a mutation in APC is synonymous with aberrant activation of 
canonical Wnt signaling since APC is an integral part of the β-catenin destruction 
complex (50).  However, previous work has shown that additional events, including K-
ras activation (51), are required for nuclear localization of β-catenin (see also 52, 53).  
This is substantiated by studies showing lack of nuclear β-catenin in early adenomas (54, 
55).  Therefore, at the initiating stages of colon cancer, β-catenin may accumulate in the 
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cytoplasm but is not at this point nuclear, and as such the β-catenin/Tcf/Lef 
transcriptional activity cannot be activated.  Thus, additional pathways must be in play 
that, upon APC mutation, are dysregulated and result in hyperplastic conditions. 
One pathway that APC has been shown to regulate is the biosynthesis of the 
signaling molecule retinoic acid (6, 56).  In the developing zebrafish intestine, APC 
mutation leads to transcriptional repression of retinol dehydrogenases, the enzymes 
which catalyze the oxidation of dietary retinol (Vitamin A) to retinaldehyde (or retinal) 
(57).  This leads to loss of retinoic acid production in the intestine.  The effect of this is 
loss of terminal differentiation, indicating that when APC is mutated, cells are unable to 
properly differentiate.  This defect can be reversed upon addition of exogenous retinoic 
acid, indicating that retinoic acid, not β-catenin, regulates cell fating in the intestine (6). 
The loss of retinoic acid production in the intestine causes a downstream signaling 
cascade that includes increases in the levels of the pro-inflammatory factor Cox-2 due to 
transcriptional misregulation of the transcription factor C/EBP-β (58).  Cox-2 catalyzes 
the conversion of arachadonic acid into prostaglandins.  One of these prostaglandins, 
PGE2, antagonizes the β-catenin destruction complex (59), leading to increased 
cytoplasmic β-catenin (Figure 1.4).  Loss of retinoic acid production also leads to 
aberrant transcription of the DNA demethylase components, which causes loss of 
terminal differentiation in the intestine (60). 
 
1.3 Retinoid Acid Synthesis and Signaling 
 
Retinoic acid has long been identified as a regulator of cell differentiation (61).  It 
regulates or promotes the differentiation of multiple cell types, including ES cells (62), 
EC cells (63), regulatory T cells (64), mesenchymal stem cells (65), olfactory neurons 
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(66), and multiple types of cancer cells, including neuroblastomas (67) and leukemia 
(68).  That RA can differentiate cancer cells suggests that these cells are trapped in an 
undifferentiated state, and it may be this aspect of their character that leads to 
hyperproliferation. 
 Retinoic acid is derived from dietary vitamin A (retinol) (69).  Vitamin A 
deficiency on an organismal level manifests itself mainly in ocular and vision defects, 
commonly night blindness, although total blindness may occur (70, 71).  On a cellular 
level, retinol is oxidized by retinol dehydrogenases to form retinal in the rate limiting step 
of RA biosynthesis.  Retinaldehyde dehydrogenases (also known as aldehyde 
dehydrogenases or ALDHs) catalyze a second oxidation step to form retinoic acid (69).  
(Retinoic acid can be further converted by oxidizing one or more of its carbon-carbon 
double bonds, but these products are thought to be metabolically inactive and this method 
used to control the amount of retinoic acid-regulated transcription (72, 73).)   
Once retinoic acid is formed in the cell, it can be used to modulate gene 
expression.  A classical RA response gene would respond to retinoic acid in the following 
manner (74, 75): RA will bind to either receptor retinoic acid receptor (binds all-trans 
retinoic acid) (76, 77) and retinoid X receptor (binds 9-cis retinoic acid) (78).  The 
receptors may have previously heterodimerized and bound DNA in the absence of RA, 
and under these conditions the heterodimer will recruit corepressors to repress RA-target 
genes.  The heterodimer binds DNA at retinoic acid receptor elements (RAREs).  Upon 
activation by retinoic acid binding, a conformational change occurs in the receptors, and 
the heterodimer will either attract transcription machinery (RNA Pol II) or coactivators 
(such as SWI/SNF and Nf1) to activate gene transcription (79, 80). 
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While there are genes that respond to RA in the way described, there are also 
genes that respond in a different fashion when RA is present.  Retinoic acid can bind to 
other receptors, such as PPARs, promoting transcription from a unique gene set (81, 82). 
Additionally, RA may produce changes in gene expression during the differentiation 
process by mediating the binding of transcriptional repressors.  The promoter and 
enhancer elements for the stem cell gene Oct4 contain RARE-motifs, which, in the 
presence of RA, are bound by orphan receptors that silence Oct4 (83).  It has also been 
hypothesized that the RAR-RXR heterodimer can prevent transcriptional activators from 
binding (84, 85).  These examples do not include the numerous secondary genes that are 
repressed by retinoic acid targets, many of which play a role in the regulation of 
differentiation and are misregulated downstream of retinoic acid loss when APC is 
mutated (58, 60).  As retinoic acid is involved in the differentiation, a process involving 
the modification of chromatin, it is likely that RA governs additional chromatin modifiers 
to regulate this process. 
 
1.4 Chromatin and Chromatin Modifiers 
 
While heritable DNA sequences determine the genes present in every cell, the 
epigenetic makeup of each cell differs greatly dependent on cell type and developmental 
stage.  It is these secondary marks on the DNA and histones that provide context about 
when gene expression is allowed (86).  Every cell carries the same contingent of DNA, 
and yet that same DNA can be directed epigenetically to cause a cell to become a vast 
array of cell types, from differentiated neurons to intestinal stem cells.  Since this process 
is so vital to every cell in the body and in every developmental change, it must be tightly 
regulated.   
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While we are still uncovering the “epigenetic code,” it is becoming increasingly 
clear that there are secondary marks both to turn genes on and to turn genes off.  DNA 
itself may undergo methylation of specific cytosine residues that serve as binding sites 
for repressors of gene expression (87), but much of the epigenetic information is encoded 
within posttranslation modifications of histone tails (88, 89).  The posttranslation 
modification (90) of residues on histone tails serve as binding sites to indicate to 
coactivators or corepressors (depending on the modification and site) that a gene should 
be activated or repressed.  These modifications are known as the “histone code” and 
being able to “read” the code allows for the proper expression of many genes, particularly 
those involved in development, differentiation, and patterning (91). 
Genes involved in development are often marked with a bivalent pattern of 
histone methylation in a phenomenon known as poising (92, 93).  These genes are 
marked in undifferentiated cells by two histone methylation marks, H3K4 methylation 
(H3K4me) and H3K27 methylation (H3K27me).  This is of interest because these two 
marks have opposing functions: H3K4 methylation marks active chromatin, where 
H3K27 methylation is indicative of silenced chromatin (94–96).  Work done has shown 
that these two marks may be found in the same nucleosome, indicating that it is not 
simply a wide chromatin swatch sampled that contains both marks.  This bivalency 
allows genes to be primed to facilitate more efficient activation or repression of needed 
pathways as the cell differentiates (92).  Genes that need to be activated will retain H3K4 
methylation, and genes that will be silenced in the differentiated cell type will undergo 
removal of the H3K4 methylation, leaving behind the repressive H3K27 methyl mark.  In 
this manner undifferentiated cells of multiple types can use chromatin markings to 
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prepare themselves for differentiation without committing to a specific cell fate. 
The proteins responsible for laying down these marks are histone 
methyltranferases (HMTs) (97).  These enzymes contain a SET domain that transfers the 
methyl group from the cofactor s-adenosylmethionine (SAM) to the terminal amino end 
of a lysine residue (98).   Lysine residues can be methylated with one, two, or three 
methyl groups, although not all HMTs will attach three methyl groups to a residue.  
Although most lysine residues can be methylated by multiple methyltransferases, most 
methyltransferases are specific to one residue (98–100).  Once methylated, the histone 
will remain methylated until either the histone is removed from the DNA, or, more 
frequently, the methyl group is removed by a histone demethylase (101).  There are two 
types of histone demethylases.  The first family utilizes an FAD-dependent reaction and 
are amine oxidases, capable only of removing mono- or dimethylation from lysine 
residues (102, 103).  The more common type of histone demethylases belong to the 
Jumonji class of proteins.  These demethylases are iron dependent and use 2-oxoglutarate 
in the hydroxylation of the methyl group from lysine residues (104, 105).  Both histone 
methyltransferases and histone demethylases are important regulators both of 
development, as is shown by defects and commonly embryonic lethality in knockouts 
(106–110) and in cancer, as is evident by many of these factors being mutated or 
misexpressed in multiple cancer types (111–118).  Because of their role in both of these 
processes, it is likely that they have an effect on cell fating. 
Histone methylation plays a vital role in regulating the changing chromatin during 
differentiation, a process that can often be misregulated in cancer.  While there appears to 
be a global loss of methylation at lysine 20 of histone H4 (H4K20me3) (119), other 
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histone methyl marks tend to be more cancer type- and gene-specific.   As many histone 
methyltransferases and demethylases are dysregulated in cancer, these methyl marks are 
frequently aberrantly placed within cancer cells.  A pattern often found in tumorigenesis 
is the epigenetic silencing of tumor suppressors, with histone methylation acting as a 
“second hit” to the wild type copy of a tumor suppressor (120, 121).  However, in some 
cancer types histone methyltransferases are transcriptionally downregulated (or absent), 
which leads to a loss of transcriptional silencing at genes that would otherwise be 
repressed (122–124).  This can cause the aberrant expression of oncogenes.  The 
misregulation of chromatin modifiers during cancer – and thus the aberrant placement of 
chromatin marks – can lead to an increased subset of dysfunctional pathway activation 
than can be accounted for solely through genetic mutations.  As such, it is necessary to 
determine how the mismanagement of these factors affects the progression of 
tumorigenesis. 
 
1.5 Polycomb Repressive Complexes and Development 
 
Polycomb group proteins are among the chromatin modifiers that control cell fate 
decisions.  These genes were first discovered in fruit flies as regulators of the hox genes 
and led to similar anterior-posterior patterning phenotypes when mutated (125).  While 
hox gene regulation is necessary for the developing embryo, Polycomb group proteins 
also play a larger role in regulating chromatin in order for proper cell fating to occur 
(126–130).  PcG proteins comprise two repressive complexes, the Polycomb repressive 
complex 2 (PRC2), which deposits the repressive H3K27 trimethyl mark, and Polycomb 
repressive complex 1 (PRC1), which is responsible for recruiting further chromatin 
modifiers to either repress binding of activators or further shut down the chromatin (131) 
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(Figure 1.5).  PRC2 contains a histone methyltransferase, Ezh2, which adds three methyl 
groups to lysine 27 of histone H3 (H3K27me3) (132).  This methyl mark is recognized by 
a chromodomain-containing member of PRC1 (Polycomb in flies and chromobox in 
vertebrates), which binds to the methylated histone (133, 134).  It is still not fully known 
how PRC1 represses target genes, although several potential mechanisms exist, including 
directly inhibiting the binding of RNA polymerase, other members PRC1 (the Ring 
proteins) ubiquitylating lysine 119 on histone H2A, or the recruitment of DNA 
methyltransferases (135–138).  It has also been suggested that PRC1 may also serve to 
mechanically compact chromatin (139). 
In keeping with their role in cell fating, full organism knockouts of Suz12, Eed, 
and Ezh2, the core members of PRC2, cause embryonic lethality in mice (106, 140, 141).  
The knockouts of the core components of PRC1 do not seem to share the same 
embryonic lethality, although they do cause physical malformations (142–144).  It has 
been theorized that PRC2 knockouts are embryonic lethal but PRC1 knockouts are not 
because redundancy of PRC1 components in the mouse genome. 
Many of the Polycomb group proteins have been implicated in cancer (145–149).  
The majority of these cases have an increase of Polycomb activity.  An increase in 
activity leading to a hyperproliferative phenotype and a loss of activity giving rise to 
lethality indicates that an optimal window of Polycomb activity is necessary for 
homeostasis (150–153).  However, it is not solely the levels of these factors that must be 
tightly regulated, but also the activity and the localization.  Proper localization of 
Polycomb group proteins (and thus the H3K27me3 mark) will turn off cell fating genes 
not required for differentiated cell types during development and differentiation (154, 
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155).  Should this mark not be found at genes that should be turned off, genes may 
differentiate into the improper cell type, or they will fail to undergo differentiation at all.  
This mark may also be improperly found at tumor suppressor genes such as cell cycle 
regulators, which should be turned on in order to maintain proper cell functions upon 
differentiation (156).  The H3K27me3 mark is found at genes in multiple different 
pathways that regulation differentiation, among them Wnt signaling, Hedgehog, Notch, 
retinoic acid signaling, FGF signaling, and the TGF pathway (157–160).  With this vast 
array of pathways under its control, it is obvious that regulation of the H3K27me3 mark – 
and thus both the expression and localization of the factors that place it – is of vital 




 The work presented in this dissertation focuses on the use of epigenetics to 
control differentiation with the intestine, on a general scale and within the context of 
mutated APC.  It also establishes further mechanisms for the regulation of retinoic acid 
biosynthesis and how RA regulates downstream effectors of retinoic acid signaling.  
Chapter 2 focuses on the histone demethylase LSD1 and the role that it plays in the 
epigenetic regulation of the retinoic acid biosynthetic machinery.  This adds an additional 
misregulated player that contributes to tumorigenesis when APC is mutated in cancers.  
Chapter 3 will introduce another epigenetic mark, H3K27 methylation, that is regulated 
by APC and misregulated downstream of loss of retinoic acid production.  We present an 
epistatic mechanism through which retinoic acid regulates this mark, which presents an 
additional paradigm for the regulation of chromatin modifiers by retinoic acid.  Chapter 4 
describes the loss of ezh2 in the developing zebrafish embryo.  This is of interest because 
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loss of ezh2 has not been previously described in vertebrate development.  This chapter 
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 CHAPTER 2 
 
 
THE ROLE OF LSD1 IN THE REGULATION 




Loss of APC in the intestine leads to loss of intestinal terminal differentiation, a 
state precipitated by lack of retinoic acid production.  The retinoic acid biosynthetic 
machinery is aberrantly repressed, leading to loss of retinoic acid, which does not allow 
the cells to undergo proper cell fate transitions.  LSD1 is a histone demethylase that can 
act to repress genes by removing the activating histone methyl mark H3K4me2.  Genes 
lacking the H3K4me2 mark are transcriptionally repressed, a phenomenon often seen in 
cancer to silence tumor suppressors and genes required for differentiation.  In this study, 
we show that LSD1 has abnormal expression patterns when APC is mutated and that it 
directly represses rdh1l, a member of the retinoic acid biosynthetic machinery.  We see 
that inhibition of LSD1 activity can restore intestinal differentiation, identifying another 
key player in the regulation of differentiation in the intestine.  We also demonstrate that 
LSD1 acts to repress rd1hl in a Lef1-dependent manner, indicating additional players in 










The methylation of lysine residues on histones not only indicates active or 
inactive chromatin states (1, 2), but also signals to proteins involved in transcription that 
binding is accessible or that binding sites are blocked (3).  This system is tightly 
regulated so as to allow for specific changes during development and differentiation (4).  
Because of this important role, transcriptional regulation by histone methylation is often 
hijacked within cancer cells to regulate gene programs to increase tumorigenesis (5). 
 Methylation at lysine 4 of histone H3 (H3K4me) is an activating methyl mark 
often associated with euchromatin (6).  Di- and trimethylated H3K4 (H3K4me2 and 
H3K4me3, respectively) are found enriched at actively transcribed promoters, whereas 
monomethylated H3K4 (H3K4me1) more often marks enhancers of genes (7).  These 
marks can be left by multiple methyltransferases, including multiple MLL proteins 
(members of the Trithorax group family) (8, 9) and the SET1 histone methyltransferase 
(10).  H3K4 methylation has the ability to recruit transcriptional activators, such as the 
ATP-dependent nucleosome remodelers CHD1 and NURF (11, 12).  The highest levels 
of H3K4 methylation are found at the transcriptional start sites of highly expressed genes, 
further linking H3K4 methylation and transcriptional activation (13, 14). 
 Until the discovery of LSD1, it was presumed that lysine methylation on histones 
was an irreversible mark.  However, the discovery of LSD1 showed the dynamic nature 
of this mark and allowed for exploration of histone demethylation (15).  LSD1 is a flavin-
dependent amine oxidase that can demethylate mono- or dimethylated histone H3 lysine 
4 or lysine 9, dependent on context (16).  When acting as a repressor, LSD1 complexes 
with the transcriptional corepressors CoREST and HDAC1/2 (17, 18) and removes the 
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activating H3K4 dimethyl mark.  LSD1 has been shown to be misregulated in multiple 
cancer types (19, 20), suggesting a role for this chromatin modifier in tumorigenesis. 
 APC mutation is the initiating step in colon cancer (21, 22).  Previous work has 
established that this is due to its regulation of retinoic acid biosynthesis, and when RA is 
not produced in the cell, the cell cannot properly differentiate (23).  Retinol 
dehydrogenases, the enzymes responsible for the catalysis of retinol to retinal, the first 
step in retinoic acid biosynthesis, are transcriptionally repressed when APC is mutated 
(24).  The misregulation of these genes is a key step in the initiation of colon 
tumorigenesis.  APC regulates the expression of these genes by relieving their repression 
by CtBP (25).  APC interacts with CtBP through the c-terminal region frequently lost in 
colon cancers, and thus, when mutated, it is unable to target CtBP1 for proteasomal 
degradation (26).  CtBP is a transcriptional corepressor that recruits additional repressors 
in order to silence genes (27, 28).  It is known to interact with several histone 
deacetylases and histone methyltransferases to methylate lysine 9 of histone H3, a mark 
of silenced chromatin (29).  CtBP has also been linked to LSD1, although this 
relationship is less clear (28). 
 The TCF/LEF proteins are a family of transcription factors that activate Wnt 
signaling and are often bound to β-catenin to activate the transcription of Wnt target 
genes (30).  Certain TCF/LEF complexes have also been shown to bind to CtBP in order 
to repress genes (31–33).  One family member, LEF1, has been reported to interact with 
multiple other partners.  LEF1 acts independently of Wnt signaling to bind ETS family 
members (34), cooperates with SMADs to coordinate BMP gene regulation (35, 36), and 
acts in concert with CDX1 to autoregulate the Cdx1 promoter (37).  Previous work done 
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in the lab has shown that lef1 levels are elevated in the apc mutant zebrafish and that lef1 
binds to the rdh1l promoter (38). 
While we have shown that the RA biosynthetic machinery is dysregulated through 
a CtBP-dependent mechanism when APC is absent, we have not been able to show a 
comprehensive mechanism for this phenomenon.  This study highlights the role of one 
player, LSD1, in the regulation of the RA biosynthetic machinery and explains a 
mechanistic basis for the role of defective cell fating when APC is mutated. 
 
2.3 Materials and Methods 
 
2.3.1 Wild type and apc heterozygous Danio rerio (zebrafish) 
 
 Wild type (Tü strain) and apc heterozygous Danio rerio (zebrafish) were 
maintained on a standard 14 hour/10 hour light/dark cycle.  (apc heterozygous zebrafish 
were a kind gift from Anna Pavlina-Haramis and Hans Clevers.)  Fertilized embryos were 
collected following natural spawning and allowed to develop at 28 oC.  All embryos were 
raised in 0.003% phenylthiourea to inhibit pigment formation starting at 24 hpf. 
 
2.3.2 Morpholino injections 
Antisense and control morpholino oligonucleotides were obtained from Gene 
Tools, LLC.  LSD1 morpholino (GGTCTGACTTCTTATTGGACAACAT) was 
solubilized in 1x Danieau buffer and injected at the 1-cell stage using 1 nl of 0.25 mM 
concentration.  Control injection (CCTCTTACCTCAGTTACAATTTATA) was done 







2.3.3 Drug treatments 
 
Embryos were placed in 3 mM LSD1 inhibitor pargyline (Sigma) or water control 
starting at 75% epiboly and drug was replaced every day. 
 
2.3.4 RNA extraction and quantitative RT-PCR 
RNA from whole embryos or adenoma tissue was isolated using Trizol 
(Invitrogen). cDNA was reverse-transcribed using Superscript III (Invitrogen). A 
template-free negative control was included in each experiment.  RT-PCR was performed 
on a Roche lightcycler.  Primers were rdh1l: 5’- GCTGCATCTGGATGTGACTG-3’, 5’- 
ACTCGACCCTTGGCTTTCTT-3’, zebrafish lsd1, 5’- 
CCCTTAAGCACTGGGATCAG-3’, 5’- ACACGAGTAGCCATTCCTTACTG-3’, 28s 
rRNA 5;-CCTCACGATCCT TCTGGCTT-3, 5’-AATTCTGCTTCACAATGATA-3’, 
human LSD1 5’- ATGTTATCTGGGAAGAAGGC-3’, 5’- 
GACCCAGGCACGACAGTA-3’, 18s rRNA, 5’- CGATTGGATGGTTTAGTGAGG-3’, 
5’- AGTTCGACCGTCTTCTCAGC-3’, DHRS9: 5′-TGGAAACTTGGCAGCCAGAA-
3′, 5′-CCAGAGACCTTTCTCCCCAA-3′. 
 
2.3.5 Whole mount in situ hybridization 
Zebrafish embryos were fixed in sucrose-buffered 4% paraformaldehyde, rinsed 
in PBST and dehydrated through an ethanol series, and stored in 100% methanol at -20 
oC.  Whole mount in situ hybridizations were carried out by standard protocol as 
previously described (21).  cDNAs were cloned into the pCR-TOPO-II vector 
(Invitrogen) and riboprobes for the indicated genes were made with digoxigenin-labeled 
UTP (Roche).   
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2.3.6 Tissue samples and western blotting 
Matched adenoma and uninvolved tissue samples were taken from FAP patients.  
Samples were dounce-homogenized in IPH buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 5 
mM EDTA, 0.5% NP-40, Protease inhibitors, phosphatase inhibitors), further 
homogenized in the FastPrep 120 (Thermo Scientific), boiled, and spun to pellet the 
debris.  For blotting, protein extracts were boiled in Nupage sample buffer (Invitrogen) 
and then separated on a 4–12% denaturing polyacrylamide gel. Proteins were then 
transferred onto a PVDF membrane, which was then immunoblotted in the antibodies α-
LSD1 (Abcam; ab-17721) and α-β-actin (Novus Biologicals). 
Zebrafish embryos were collected at 72 hpf and placed in an SDS lysis buffer (10 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton-X, 0.1% SDS) and 1x protease inhibitor 
mixture (Sigma).  The embryos were homogenized using the Tissuelyzer II (Qiagen).  
Lysates were analyzed as above. 
 
2.3.7 siRNA knockdown 
SW480 cells were cultured as recommended by the ATCC.  For silencing of 
LEF1, the sequences of the small interfering RNAs were: sense, 5’- 
CACCUCAGGUCAAACAGGAdTdT-3’, antisense, 5’- 
UCCUGUUUGACCUGAGGUGdTdT-3’.  Transfection experiments were performed 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
recommendations.  Following transfection with 100 nM or 200 nM siRNA, cells were 





2.3.8 Chromatin immunoprecipitation 
 
ChIP was performed as described earlier (39).  ChIP in SW-480 cells were 
performed with antibody α-LSD1 (Abcam; ab-17721) and rabbit IgG (control).  Primers 




 Previous work done in the lab has shown that CtBP is a key player in the 
transcriptional repression of RDH1L when APC is mutated (23).  Though CtBP 
associates with multiple transcriptional co-repressors, we had not yet determined an 
epigenetic mechanism for the repression.  As CtBP had been shown to interact with the 
lysine demethylase LSD1, we wanted to assess whether LSD1 may play a role in the 
repression of rdh1l.  We began by determining the effect of APC mutation on LSD1 
levels.  In order to do this, we obtained colon polyp samples and grossly uninvolved 
tissue from patients harboring an APC mutation and probed for expression of LSD1 by 
Western blotting (Figure 2.1).  In patient 1, grossly uninvolved tissue (U) had relatively 
low expression of LSD1 and high expression of LSD1 in adenoma tissue (A).  Patients 2 
and 3 displayed little to no expression of LSD1 in uninvolved tissue and showed 
increased expression in adenomas.  Patient 4 displayed no change in LSD1 expression, 
indicating that while LSD1 is often misexpressed, it is not solely responsible for the 
effect observed when APC is mutated.  Similarly, lsd1 protein was upregulated in apcmcr 
zebrafish embryos compared to very low levels of expression in apc wild type siblings 
(Figure 2.1). 
 We also wanted to observe the effect of APC mutation on LSD1 transcript levels.  
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Quantitative RT-PCR was performed on RNA extracted from adenomas and grossly 
uninvolved tissue (Figure 2.1).  Several of the patients displayed significantly increased 
levels of LSD1 mRNA in the adenoma samples, indicating that LSD1 is misregulated 
transcriptionally when APC is mutated.  As with protein levels, not all samples show 
effects in LSD1 RNA levels when APC is mutated, testifying to the need of addition 
players in the progression of colon carcinogenesis.  As in adenoma samples, we found 
that lsd1 is transcriptionally upregulated when apc is mutated in zebrafish when assayed 
by whole mount in situ hybridization (Figure 2.1). 
 Previous studies have shown that the retinol dehydrogenases are misregulated at a 
transcriptional level when APC is mutated.  This loss of RDH gene product in cells 
leaves them incapable of differentiating, indicating that RA is necessary for proper cell 
fate decisions (22).   Because LSD1 can play a role in epigenetic silencing through its 
role in regulating histone methylation, we wanted to determine whether it plays a role in 
the regulation of retinol dehydrogenases when APC is mutated.  To determine whether 
lsd1 plays a role in the regulation of rdh1l, we injected lsd1 morpholino into apcmcr 
zebrafish embryos and tested rdh1l transcript levels by RT-PCR (Figure 2.2).  Loss of 
lsd1 increased levels of rdh1l, indicating that lsd1 plays a role in its transcriptional 
regulation.  We also used the lsd1 inhibitor pargyline in order to abrogate the enzymatic 
demethylase activity of lsd1 and tested rdh1l transcription by RT-PCR.  Inhibition of lsd1 
increased levels of rdh1l, although not to the same extent as morpholino knockdown 
(Figure 2.2). 
We have previously demonstrated that addition of exogenous retinoic acid is 
capable of rescuing terminal differentiation defects in apcmcr zebrafish (21).  Because lsd1 
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plays a role in the regulation of retinol dehydrogenases, we wanted to determine whether 
inhibition of lsd1 was also capable of rescuing terminal differentiation.   We used the 
apcmcr zebrafish to study this role of lsd1.  To ascertain the role of lsd1 in intestinal 
differentiation, we used pargyline to inhibit the activity of lsd1 and performed in situ 
hybridization for the terminal differentiation marker fabp2 (i-fabp) (Figure 2.2).  
Zebrafish harboring the apc mutation do not display expression of this marker, but when 
these embryos are treated with pargyline, they regain expression of fabp2, indicating that 
histone lysine demethylation by lsd1 plays a role in the differentiation of the zebrafish 
intestine. 
 Previous work in the lab has shown that during normal intestinal differentiation, 
lef1 and lsd1 interact to form a transcriptional activation complex that activates the rdh1l 
promoter in the presence of RA (40).  Like lsd1, when apc is mutated lef1 is aberrantly 
expressed (38) and as the rdh1l promoter contains lef1 binding sites, we posited that lsd1 
acts directly to repress transcription of rdh1l.  To test this, we performed chromatin 
immunoprecipitation on SW480 cells and examined LSD1 occupancy (Figure 2.3).  We 
found that LSD1 does bind the RDH1L promoter, suggesting a direct repression of the 
gene.  This is consistent with the data that depletion of lsd1 by morpholino increases 
expression of rdh1l.  When LEF1 siRNA was transfected into the cells, LSD1 binding at 
the RDH1L promoter was abolished, indicating that LEF1 presence is necessary for 
LSD1 binding and suggesting that LEF1 and LSD1 are interacting to suppress RDH1L 









 Retinoic acid is required for proper cell fating.  We have previously shown that 
the retinol dehydrogenases are misregulated when APC is mutated, leading to loss of 
retinoic acid production and loss of terminal differentiation in the intestine (22).  
Restoration of retinoic acid signaling by the addition of exogenous retinoic acid is 
capable of restoring differentiation to the intestine, indicating that RA is responsible for 
this differentiation.  What remains unclear, however, is how the machinery of retinoic 
acid production is regulated.  In this study, we identified a factor, LSD1, that regulates 
the expression of some of this machinery at an epigenetic level. 
 In order to determine the role of LSD1 in the regulation of retinoic acid 
production when APC is mutated, we utilized the apcmcr zebrafish line as well as 
adenoma samples from FAP patients that harbor a germline APC mutation.  We found 
that LSD1 is increased at the mRNA and protein level when APC is absent, both in the 
context of apcmcr zebrafish and in patient adenomas.  This novel finding created a 
platform whereby we could elucidate the epigenetic regulation of retinoic acid production 
machinery.  As this was evaluated in adenomas, where β-catenin is not yet nuclear, and in 
apcmcr zebrafish, which also lack nuclear β-catenin, this demonstrates that misregulation 
of LSD1 occurs outside of an activated Wnt context.  This also adds another layer of 
chromatin modification that is misregulated when APC is mutated.  As we observe more 
of these factors being misregulated in the context of APC mutation, it brings into light a 
larger role for APC in the regulation of chromatin.  As it is becoming obvious that 
changes in chromatin are necessary for the changes that occur during differentiation, this 




 LSD1 is a lysine demethylase that can demethylate H3K4me2 (11, 12).   We 
wanted to determine whether LSD1 was acting within this role to repress the retinoic acid 
biosynthetic machinery when APC was mutated.  To do this, we manipulated lsd1 levels 
and activity in apcmcr zebrafish to test the levels of rdh1l transcript.  Rdh1l levels are high 
in wild type siblings, but very low in zebrafish embryos containing mutated apc.  When 
these embryos are injected with lsd1 morpholino, the rdh1l level rises, indicating that the 
high levels of lsd1 in apcmcr zebrafish play a role in this misregulation.  Similarly, 
treatment of apcmcr embryos with pargyline, an inhibitor of lsd1 demethylase activity, also 
leads to increased levels of rdh1l transcript.  This finding indicates that the demethylase 
activity of lsd1 is necessary for the misregulation of rdh1l.  Importantly, neither of these 
actions completely restores rdh1l levels, indicating that lsd1 is one of multiple factors 
regulating expression of rdh1l.  Because levels of other chromatin modifiers are 
misregulated when apc is absent, it is likely that lsd1 acts in concert with such factors to 
aberrantly repress the rdh1l promoter. 
In order to determine whether this was a direct effect, we performed chromatin 
immunoprecipitation on SW480 cells to determine if LSD1 occupies the RDH1L 
promoter.  SW480 cells are colon cancer cells harboring an APC mutation that closely 
mimics the mutation found most frequently in human colon cancers.  We found that 
LSD1 does occupy the RDH1L promoter in these cells.  This result, taken in concert with 
the finding that LSD1 activity is necessary, suggests that LSD1 actively demethylates 
histones at the RDH1L promoter to repress transcription.  This provides the basis of an 
epigenetic mechanism for the transcriptional repression of RDH1L when APC is mutated.  
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Knowing the epigenetics behind the repression of RDH1L unlocks LSD1 as a potential 
drug target in the treatment of syndromes with mutated APC.  While further examination 
in other retinoic acid responsive tissues, such as the eye, would be required to determine 
whether this phenomenon is extant in tissues other than the intestine and how inhibition 
of LSD1 activity would affect the homeostasis of these tissues, it is likely that this effect 
would be concentrated in tissues negatively affected by APC loss. 
These results also have implications for the formation of an LSD1/LEF1 complex 
in the absence of wild type APC.  These factors appear to form a complex that activates 
RDH1L when APC is present (40), but switches the gene to a repressed state when APC 
is mutated.  Although it has been previously shown that LSD1 is capable of switching 
between demethylating methylated H3K9 (and thus activating) and methylated H3K4 
(and thus repressing), loss of APC adds a new context wherein this switch can take place.  
Though it is unclear what is causing this switch, the implications of this change directly 
affect the synthesis of retinoic acid and terminal differentiation of the intestine.   
Rdh1l loss disrupts retinoid biosynthesis, a process required for the terminal 
differentiation of the intestine.  Because LSD1 directly represses transcription of rdh1l, 
we wanted to determine whether inhibition of LSD1 activity would be capable of 
restoring terminal intestinal differentiation.  Apcmcr zebrafish lack staining for fabp2, a 
marker for terminal intestinal differentiation, but apcmcr embryos treated with pargyline 
show restored staining of fabp2.  This suggests that LSD1, through its direct 
transcriptional repression of rdh1l, is one of several factors responsible for loss of 
terminal differentiation when APC is mutated.  This further cements LSD1 as a potential 
drug target when APC is mutated.  As inhibition of LSD1 demethylase activity is 
43 
 
sufficient to restore intestinal differentiation in the absence of APC, abrogation of LSD1 
demethylase activity may restore colon cancer cells with mutated APC to a more 
differentiated and less proliferative state. 
We propose a model whereby aberrant expression of LSD1 in the presence of 
mutated APC forms a complex containing Lef1, which leads to direct repression of rdh1l, 
leading to loss of retinoic acid production and loss of terminal differentiation in the 
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APC AND RETINOIC ACID IN THE REGULATION  
OF POLYCOMB-MEDIATED HISTONE  




The c-terminal truncation of APC is the initiating event in 85% of colorectal 
cancer cases.  Although it was long thought that this event was synonymous with the 
nuclear localization of β-catenin and subsequent transcription of TCF/Lef targets, more 
recent work has shown that additional events are needed for β-catenin to be found in the 
nucleus and that this happens further in the progression of tumorigenesis.  Recent work 
has also clarified the ability of APC, through its regulation of retinoic acid biosynthesis, 
to control the chromatin modifying DNA demethylase components.  The work presented 
herein expands upon the role of APC and retinoic acid in the control of chromatin by 
introducing an additional epigenetic mark controlled by APC: H3K27 trimethylation.  We 
show that APC, through its regulation of retinoic acid biosynthesis, regulates the levels of 
H3K27me3.  However, unlike the DNA demethylase components, the factors responsible 
for the deposit of H3K27me3 are not regulated transcriptionally by retinoic acid, but are 
regulated through Cox-2, a downstream target of RA signaling.  Although we have 
previously shown that, in the absence of APC, increased levels of Cox-2 leads to an 
increase in β-catenin levels, the Cox-2-mediated regulation of H3K27me3 occurs
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independent of β-catenin. 
 
3.2 Introduction 
 APC is necessary for the proper differentiation of intestinal cells (1).  This is due 
to the fact that APC is a major regulator in the biosynthesis of retinoic acid, and when RA 
is lost, cells are no longer able to properly differentiate (2).  Upon addition of exogenous 
RA, gut cells once again undergo terminal differentiation.  However, the mechanisms by 
which RA influences cell fating remain unclear. 
 APC, through its control of RA biosynthesis, can control cell fating through the 
transcriptional regulation of chromatin modifiers, as indicated by the finding that APC 
mutation results in increased levels of the DNA demethylase components (3).  This 
misregulation caused defective cell fating and was rescued by the addition of RA.  
Because downstream effects of RA can be felt amongst chromatin modifiers, it is 
possible that it is through this mechanism that RA prepares cells to promote proper cell 
fate decisions. 
 The Polycomb group proteins are chromatin modifiers that are necessary for 
proper embryonic development (4–6).  Polycomb group proteins were identified in flies 
as regulators of Hox genes (7) and, when mutated in flies, give rise to phenotypes 
wherein body segments are aberrantly placed.  The Hox genes regulate anterior-poster 
body patterning (8) and are found in vertebrates in seven or eight clusters, determined by 
genome duplication (9, 10).  Hox gene clusters are found and regulated linearly in the 
genome (11), with the genes with the smallest numerator regulating patterning most 
anterior in the body and the genes with the largest numerator most posterior (12, 13).  
Several of these genes are transcriptionally regulated by retinoic acid and dysregulated 
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upon mutation of APC (14). 
 The Polycomb repressive complex 2 lays down the H3K27 trimethyl mark 
(H3K27me3) (15).  This mark represses transcription and is often found at key 
developmental regulator genes (4–6, 16).  However, there is not yet a clear method of 
genome-wide recruitment for PRC2.  While several processes have been discovered for 
specific loci (17–19), these methods do not seem to bear out on a global level.  Although 
Polycomb responsive elements (PREs) have been discovered in flies (20, 21), the method 
of recruitment to these sites is in question, and no PRE has been discovered in mammals.  
While the method of recruitment is unclear, there is no doubt that it would need to be 
kept under tight regulation during development and differentiation to ensure proper 
placement of H3K27me3.  The need for proper regulation of these factors is corroborated 
by the loss of PRC2 members being embryonic lethal in mice (22–24). 
 Knowing the role that RA plays in the regulation of chromatin modifiers to 
promote proper cell fating and the role that retinoic acid plays in the transcriptional 
regulation of Hox genes, we wanted to determine whether it plays a role in the regulation 
of H3K27me3, the mark laid down by PRC2.  This study will describe the role of RA in 
the regulation of H3K27 trimethylation and how this mark is affected when APC is lost. 
 
3.3 Materials and Methods 
 
3.3.1 Wild type and apc heterozygous Danio rerio (zebrafish) 
Wild type (Tü strain) and apc heterozygous Danio rerio (zebrafish) were 
maintained on a standard 14 hour/10 hour light/dark cycle.  (apc heterozygous zebrafish 
were a kind gift from Anna Pavlina-Haramis and Hans Clevers.)  Fertilized embryos were 
collected following natural spawning and allowed to develop at 28 oC.  All embryos were 
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raised in 0.003% phenylthiourea to inhibit pigment formation starting at 24 hpf. 
 
3.3.2 Morpholino microinjections 
 Antisense and control morpholino oligonucleotides were obtained from Gene 
Tools, LLC. APC splice blocking morpholino (AGATGTATCTTACCTTCTGCACCTC) 
was solubilized in 1x Danieau buffer and injected at the 1-cell stage using 3 nl of 0.25 
mM concentration.  Ezh2 splice blocking morpholino 
(ATTGATCTAACCTCTCTGGTTCCAC) and control morpholino 
(ATATACATTGTCTCACCTCCATCTC) were solubilized in 1x Danieau buffer and 
injected at the 1-cell stage using 2 nl of 0.75 mM concentration. 
 
3.3.3 Drug treatments 
Embryos were treated with 1 μm all-trans retinoic acid (Sigma) or DMSO for 1 
hour at 6, 30, and 56 hpf.  NS-398 treatment was similar except at 10 μM (Cayman 
Chemical).  Embryos were chemically dechorionated and treated with 10 μM 
diethylaminobenzaldehyde (Sigma) at 30 hpf consistently until protein harvesting at 96 
hpf. 
 
3.3.4 RNA extraction/RT-PCR 
 
RNA was isolated from embryos using an RNeasy kit (Qiagen) and then 
synthesized with the Superscript III kit (Invitrogen).  RT-PCR was performed on a Roche 
light cycler.  Primers were ezh2 5’-GGTATTGAACGTGAAATGGAAAT-3’, 5’-
TGTAAGGCATTTGTTCAGAGAGG-3’; utx 5’-CTGGATGCACCATACAGTGG-3’, 
5’-ATGGCGTAGCTGTCCTTGTT-3’; suz12l 5’- CGGTGAAGTCCTACTCCCTTC-3’, 
5’-CTGGTGGTCATGCCATTGT-3’; ezh1 5’-AGGATGGAGGAAGTGTCAGG-3’, 5’-
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CTCTCTTCTTCCACTCCAGCA-3’; eed 5’-AGACACTCCCACCAACACG-3’, 5’-
CACTTCTTGGACTTCCACTTCC-3’; ef1α 5’-CCTTCGTCCCAATTTCAGG-3’, 5’-
CCTTGAACCAGCCCATGT-3’, i-fabp 5’- CAACGTGAAGGAAGTCAGCA-3’, 5’- 
GGTGACGCCCAGAGTAAAGT-3’;  28s rRNA 5’-AAACCAACCCGGAGAAGC-3’, 
5’-CGCGAGATTTACACCCTCTCT-3’. 
 
3.3.5 Whole mount in situ hybridization 
Zebrafish embryos were fixed in sucrose-buffered 4% paraformaldehyde, rinsed 
in PBST and dehydrated through an ethanol series, and stored in 100% methanol at -20 
oC.  Whole mount in situ hybridizations were carried out by standard protocol as 
previously described (2).  cDNAs were cloned into the pCR-TOPO-II vector (Invitrogen), 
and riboprobes for the indicated genes were made with digoxigenin-labeled UTP 
(Roche).   
 
3.3.6 Cell culture and siRNA knockdown 
SW480 cells were purchased from ATCC and grown according to the guidelines 
of the manufacturer.  Transfection experiments were performed with Lipofectamine 
RNAiMax (Invitrogen) according to the manufacturer’s recommendation.  Transfection 
was performed at the time of seeding and after transfection, cells were incubated for 120 
hours and then harvested for western blot analysis. 
β-catenin and control siRNA were obtained from Cell Signaling. 
 
3.3.7 Western blotting 
 Zebrafish embryos were collected at 72 or 96 hpf and placed in an SDS lysis 
buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton-X, 0.1% SDS) and 1x 
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protease inhibitor mixture (Sigma).  The embryos were homogenized using the 
Tissuelyzer II (Qiagen).  Lysates were quantified using the DC protein assay (Bio-Rad).  
Samples were run through Tris-glycine 4-12% gradient NuPage gels using the MES 
buffer (Invitrogen) and transferred to PVDF membrane.  Blots were probed using the 
following primary antibodies: rabbit α-H3K27me3 (Millipore), mouse α-H3K27me3 
(Abcam), rabbit α-H3 (Abcam), and rabbit α-beta-catenin (Abcam).  
 Protein samples from cells were harvested at 120 hours posttransfection in RIPA 
buffer (50 mM HEPES, pH 7.6, 1 mM EDTA, 0.7% deoxycholate, 1% NP-40, 0.5 M 
LiCl and 1.5x protease inhibitors) and spun down to pellet debris.  Lysates were 
quantified and analyzed as with zebrafish embryos above. 
 Blots were quantified by calculating intensity in Adobe Photoshop for H3K27me3 





APC mutation has been shown to dysregulate multiple chromatin modifying 
pathways (3, 25).  This dysregulation has caused loss of terminal differentiation in the 
intestine, indicating a role for chromatin in the process of differentiation.  It is likely that 
APC regulates other chromatin marks and modifiers in order to promote proper cell 
fating.  We wanted to examine the effects of apc loss on the regulation of histone 3 lysine 
27 methylation.  To evaluate the effect of apc mutation on H3K27 methylation levels, 
apcmcr zebrafish and apc wild type siblings were grown to 72 hpf, at which point protein 
was extracted from whole embryos.  Extracts blotted for levels of H3K27me3 show 
decreased levels of this histone methylation in apcmcr embryos, indicating a role for apc in 
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the regulation of histone methylation (Figure 3.1).  Because APC is a member of the β-
catenin destruction complex (26), we wanted to determine whether the activation of the 
β-catenin/TCF/Lef signaling pathway was playing a role in this change in histone 
methylation.  To test this, β-catenin was knocked down in SW480 cells.  While β-catenin 
protein levels are greatly diminished, H3K27me3 levels are unchanged (Figure 3.1), 
suggesting that apc regulates this histone methylation through a β-catenin-independent 
pathway. 
One of the hallmarks of apc loss in zebrafish is loss of terminal differentiation in 
the intestine (2).  While these embryos retain expression of the primordial gut marker 
gata6, they lose expression of i-fabp, the marker for terminally differentiated gut.  We 
wanted to determine whether the decreased levels of H3K27me3 under conditions of 
APC mutation contribute to this loss of cell fating. To assay this, we used a splice-
blocking morpholino for ezh2, the H3K27 methyltransferase.  Wild type embryos 
injected with ezh2 morpholino phenocopy the apc mutant phenotype in loss of terminal 
differentiation of the intestine.  Whole mount in situ hybridization for gata6 is unchanged 
in ezh2 morphants, but i-fabp is deficient in these embryos (Figure 3.2).  We have 
previously shown that in conditions of apc mutation, it is loss of retinoic acid production 
that leads to loss of terminal gut differentiation (27).  This defect can be rescued by the 
addition of all trans retinoic acid to the developing zebrafish.  Because ezh2 morphants 
also experience a loss of terminal gut differentiation, this raised the question of whether 
ezh2 morphant zebrafish are also retinoic acid deficient.  In order to test the relationship 
between retinoic and ezh2, ezh2 morphants were treated with retinoic acid to determine i-
fabp levels.  Quantitative RT-PCR of i-fabp in ezh2 morphants treated with retinoic acid 
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shows no significant increase as compared to ezh2 morphants that are control treated 
(Figure 3.2), indicating that both retinoic acid and ezh2 are necessary for terminal 
differentiation of the intestine or that retinoic acid is upstream of ezh2 activity. 
Many of the defects observed in apcmcr zebrafish are caused by loss of retinoic 
acid and can therefore be restored by the addition of exogenous RA.  The ezh2 morphant 
appears to phenocopy some of these defects, but these defects cannot be rescued by RA.  
This led us to question whether ezh2 and RA are in convergent pathways or whether they 
reside in the same pathway, with RA acting upstream of ezh2’s regulation of H3K27 
methylation.  To examine this, wild type zebrafish were injected with apc morpholino 
and treated with all-trans retinoic acid.  Protein blots show that apc morphants treated 
with ATRA have increased levels of H3K27me3, whereas apc morphants control treated 
with DMSO have very low levels of H3K27me3 (Figure 3.3).  To determine whether RA 
was sufficient for the regulation of H3K27me3, wild type embryos were treated with 
DEAB, an inhibitor of retinoic acid biosynthesis, and protein was extracted from whole 
embryos at 96 hpf.  Protein blots show that inhibition of retinoic acid biosynthesis is 
sufficient to decrease in the levels of H3K27me3 (Figure 3.3). 
Previously examined key regulators of differentiation-inducing programs have 
been determined to be transcriptionally misregulated when APC is mutated (3).  In these 
cases, loss of retinoic acid is responsible for changes in the transcript levels of the 
components.  To determine whether RA plays a role in the transcriptional regulation of 
PRC2 components (Ezh2/Ezh1, Suz12, and Eed) or the H3K27 demethylase, Utx, RNA 
was extracted from apcmcr zebrafish and wild type siblings, and we performed 
quantitative RT-PCR for the above mentioned transcripts.  None of the transcripts 
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showed significant changes when APC is mutated (Figure 3.4).  PRC2 interacting 
partners Rbbp4, Jarid2a, and Jarid2b also show no significant change in transcript levels 
when apc is mutated (data not shown). 
As retinoic acid does not directly affect transcription of PRC2 components, we 
explored other pathways it affects.  Previous work done in the lab has elucidated a 
pathway whereby the loss of retinoic acid signaling caused by mutation of APC affects 
Cox-2 (28).  We wanted to determine if it was this role of RA that was affecting levels of 
H3K27me3.  To do so, we treated apcmcr zebrafish embryos with the Cox-2 inhibitor NS-
398.  Similar to the results we saw with treatment with exogenous RA, blocking Cox-2 
increased levels of H3K27me3 in the apc mutants (Figure 3.4), indicating that Cox-2 is 
an intermediary in the regulation of histone methylation by RA.   
 
3.5 Discussion 
We have previously shown that APC plays a role in the regulation of certain 
chromatin marks and by so doing, promotes proper cell fating decisions (3).  As such, 
when APC is mutated, defective cell fating occurs.  In this study we investigate the role 
of APC in the regulation of an additional chromatin mark, the trimethylation of histone 
H3 at lysine 27, and how it affects cell fating in the intestine.   
 This work demonstrates that loss of APC results in decreased levels of 
H3K27me3.  The H3K27me3 mark occupies numerous pathways involved in the 
differentiation of the intestine, and misregulation of these pathways has the potential to 
cause defective cell fating.  The fact that there are decreased levels of this chromatin 
mark is of interest because it increases the collection of chromatin marks and modifiers 
that are misregulated in the context APC mutation.  While misregulation of chromatin 
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marks is something often seen in cancer, loss of methylation at histone 3 lysine 27 has the 
profound potential to cause complications in the transition from progenitor to terminally 
differentiated cells.  The occupancy of this mark at most of the pathways that regulate the 
formation of multiple types of differentiated intestinal cells (4) highlights the necessity of 
proper regulation of this mark during this transition.  Loss of H3K27me3 suggests that 
these pathways cannot be turned off, leading to aberrant transcription of signaling 
pathways for multiple cell types. 
 Hypomorphism of ezh2 in the zebrafish causes loss of intestinal differentiation, a 
retinoic acid deficient phenotype and one hallmark of APC mutation.  However, in apcmcr 
zebrafish and other retinoic acid deficient models, treatment with exogenous retinoic acid 
rescues this loss of differentiation, which does not occur in ezh2 morphants.  This is the 
first model we have examined in which RA lacks the ability to restore intestinal 
differentiation.  This implies that retinoic acid requires other cellular factors to promote 
terminal differentiation, among them being ezh2.  It also signifies that H3K27me3 is 
necessary for terminal differentiation of the intestine. 
We have determined from previous work that defective cell fating due to mutated 
APC is mediated through a loss of retinoic acid signaling.   We have also previously 
shown that chromatin modifiers responsible for other chromatin marks are regulated by 
RA, so we wanted to determine whether RA also plays a role in the regulation of the 
H3K27me3 mark.  We show that treatment of APC deficient fish with RA is sufficient to 
increase levels of H3K27me3, indicating that RA does play a role in the regulation of this 
mark.  Chemical inhibition of RA biosynthesis is also sufficient to decrease levels of 
H3K27me3, although not to the extent that APC mutation does, indicating that there may 
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be other players involved when APC is mutated.  Although we have previously identified 
chromatin modifiers through which RA controls cell fating, these findings give additional 
insights into how RA controls differentiation.  As the knowledge of RA regulating 
chromatin modifiers grows, we will be able to better understand the pathways through 
which it regulates cellular differentiation events. 
 The previous findings are all consistent with the method by which APC mutation 
affects the DNA demethylase components.  As is common with retinoic acid regulation, 
the DNA demethylase components are transcriptionally regulated by RA, and thus are 
misregulated at the transcriptional level when APC is mutated.  However, the regulators 
of H3K27 trimethylation differed in this case.  None of the PRC2 components (Ezh2, 
Ezh1, Eed, or Suz12) nor the H3K27 demethylase (Utx) are transcriptionally affected by 
loss of APC.  We also saw no change in the PRC2 interacting partners Rbbp4 or Jarid2 
(two isoforms, Jarid2a and Jarid2b, exist in zebrafish) (29, 30).  We conclude that there 
must be additional players in the APC-mediated regulation of the H3K27me3 and that 
RA does not regulate the PRC2 components directly.  This diverges from the way RA 
regulates many components, adding new layers through which retinoic acid regulates 
chromatin modifiers during differentiation.  This may also explain why addition of 
exogenous retinoic acid failed to rescue gut differentiation in ezh2 morphants.   
 Previous work done in the lab has shown that RA regulates C/EBP-β and through 
this regulation affects the expression of the proinflammatory protein Cox-2 (28).  
Because we see that RA regulates PRC2 indirectly, we wanted to determine whether it 
took advantage of this pathway to regulate H3K27 methylation.  We saw that this mark 
changed when treated with Cox-2 inhibitor, indicating that RA uses its control of this 
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pathway to govern levels of H3K27me3.  This also led us to ask whether β-catenin plays 
a role in this regulation.  We have shown previously that the misregulation of Cox-2 
when APC is absent can lead to an upregulation of β-catenin, and we wanted to determine 
whether this played a role in the regulation of H3K27me3 (28).  We found that 
knockdown of β-catenin when APC is mutated does not affect H3K27me3 levels, which 
denotes that Cox-2 plays additional roles not related to β-catenin stabilization in the 
context of mutated APC.  This may reveal an additional role for Cox-2 in the regulation 
of cell fating and epigenetics.  This is additional evidence that the misregulation of 
H3K27 methylation takes places in the absence of activated Wnt and thus clarifies further 
pathways aberrantly regulated upon APC mutation that are not dependent on β-catenin.  
This also raises the potential for H3K27 trimethylation to be regulated in response to 
increased inflammatory signals.  Colon cancer is frequently associated with inflammation 
in the intestine, and patients who have a family history are twice as likely to develop 
colon cancer if they already suffer from inflammatory bowel diseases (31).  Although 
multiple proinflammatory pathways affect colon cancer development, Cox-2 is an 
important factor in colon tumorigenesis (32).  Other work has shown that, in 
macrophages, levels of H3K27me3 can be affected through proinflammatory pathways 
(33), although in this study levels of histone demethylases were changed, an effect we do 
not see when APC is mutated.  However, the implications of Cox-2 involvement in the 
regulation of H3K27 trimethylation add potential new insights for how inflammation 
promotes colon tumorigenesis. 
 Our data present a continuation of the story we began with Rai et al. in 
demonstrating that APC controls cell fate decisions through controlling chromatin 
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modifiers.  However, these data present a unique aspect in that, unlike the DNA 
demethylase described in Rai et al., retinoic acid affects H3K27 methylation indirectly 
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 CHAPTER 4 
 
 
THE ROLE OF EZH2 AND HISTONE METHYLATION  




The Polycomb group proteins are necessary for the development of the embryo 
and play a role in cellular differentiation.  This family is divided into two complexes, 
Polycomb repressive complex 1 and Polycomb repressive complex 2, and acting in 
concert these complexes regulate gene expression to allow for proper embryogenesis.  
While knockouts in Drosophila have been characterized, PRC2 knockout mice are 
embryonic lethal.  While this supports their necessity in the regulation of development, it 
leaves gaps in our understanding of the specific roles that they play in the regulation of 
development.  Here, we use zebrafish to present a model of vertebrate development with 
decreased levels of ezh2, the catalytically active subunit of PRC2.  This study 
characterizes loss of ezh2 in the developing vertebrate embryo.  We show that loss of 
ezh2 leads to morphological defects in the spine and loss of cartilage formation in the jaw 
and fins.  This model also shows that loss of ezh2 allows for normal development of 
some organ systems but negatively affects the development of others, highlighting tissue 
specificity for ezh2.  This study also brings into light the role of ezh2 in the development 





Proper regulation of chromatin during development and cellular programming is 
necessary to enact programs for cell differentiation and stem cell maintenance (1).  The 
transcriptional timing of differentiation programs must be carefully regulated in order to 
ensure proper development in both organogenesis and for development of the organism 
as a whole (2).  When these programs are dysregulated, the animal can fail to properly 
form organ systems and may become nonviable (3–5).  The Polycomb group proteins are 
among the factors that regulate this system to provide proper development. 
 The Polycomb group proteins were first discovered in flies to regulate the Hox 
genes (6–8).  Hox genes are developmental transcription factors that regulate the anterior-
posterior axis and segmental identity (9).  While the Polycomb group proteins are 
necessary regulators during development, multiple phenotypes are seen when they are 
lost.  Some of the defects observed include defects in neural tube formation, seen in 
Jarid2-null mice (10); left-right asymmetry, in chicken embryos devoid of Pcl2 (11); and 
a susceptibility to lung and liver tumorigenesis, in adult mice lacking Cbx7 (12).  
Knockout of some of the Polycomb group proteins display no defects at all (13), whereas 
others, including all of the core members of members of PRC2, are indispensible for 
development (3, 14–16). 
Polycomb group proteins reside in two complexes: the Polycomb repressive 
complex 1 (PRC1) and the Polycomb repressive complex 2 (PRC2) (17).  PRC2 lays 
down the repressive H3K27me3 mark (18), which is recognized by a member of PRC1 
containing a chromodomain (19).  PRC1 then lays down further repressive marks (13, 
20).  In this manner the Polycomb group proteins reprogram chromatin to set in motion 
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pathways that promote proper cell differentiation. 
 PRC2 is composed of 4 proteins: the catalytically active histone methyltransferase 
Ezh2, Eed, zinc finger and regulatory factor Suz12, and histone binding protein 
RbAp46/48 (17), although RbAp46/48 may not be consistently found with the other 
complex members (21).  Although there are individual cases of how PRC2 is recruited to 
silence certain genes (mostly notably ncRNA) (22–24), there is no clear mechanism of 
action for the recruitment of this complex on a genome-wide scale.   During 
development, this complex occupies many genes involved in pathways necessary for 
development, including Hedgehog, Fox, and Sox pathways; FGF; and Notch signaling 
(25).   Thus, proper regulation and recruitment of PRC2 during development is vital for 
development. 
 Ezh2 contains a SET domain and is responsible for methyltransferase activity 
observed in PRC2.  Unlike many histone methyltransferases, Ezh2 is capable of placing 3 
methyl groups on a lysine residue (26, 27).  Ezh2 also has the ability to bind RNA at high 
affinity (28), although it does so at low specificity, human Ezh2 being able to bind RNA 
from multiple species (29).  It has been hypothesized that this binding ability is required 
for recruitment to specific gene loci. 
 A tight regulation must be kept on these factors as is shown by their frequent 
mutation in multiple cancer types (30–35).  Ezh2 has been found mutated in several 
cancer types, including lymphoma, bladder, prostate, and breast cancer (36–46).  Ezh2 
knockout mice are embryonic lethal, indicating the necessity of this factor in early 
development (3).  In order to study the role of H3K27me3 regulation, we utilized 
developing zebrafish to study the effect of loss of Ezh2 (the H3K27 methyltransferase) to 
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better understand its role. 
 
4.3 Materials and Methods 
4.3.1 Wild type Danio rerio (zebrafish) 
 Wild type (Tü strain) Danio rerio (zebrafish) were maintained on a standard 14 
hour/10 hour light/dark cycle.  Fertilized embryos were collected following natural 
spawning and allowed to develop at 28 oC.  All embryos were raised in 0.003% 
phenylthiourea to inhibit pigment formation starting at 24 hpf unless otherwise indicated. 
 
4.3.2 Morpholino and mRNA microinjections 
 Antisense and control morpholino oligonucleotides were obtained from Gene 
Tools, LLC.  Ezh2 splice blocking morpholino 
(ATTGATCTAACCTCTCTGGTTCCAC) and control morpholino 
(ATATACATTGTCTCACCTCCATCTC) were solubilized in 1x Danieau buffer and 
injected at the 1-cell stage using 2 nl of 0.75 mM concentration. The zebrafish ezh2 
construct was cloned into the pCR-TOPO-II vector (Invitrogen).  The construct with 
linearized with EcoRV (Fermentas) and transcribed using the T7 mMessage mMachine 
(Ambion) according to the manufacturer’s protocol.  mRNA was injected at 25 ng/μl 
with morpholino as above. 
 
4.3.3. RNA extraction/PCR 
 
RNA was isolated from embryos using an RNeasy kit (Qiagen) and then 
synthesized with the Superscript III kit (Invitrogen).  Primers for verification of ezh2 




4.3.4 Whole mount in situ hybridization 
Zebrafish embryos were fixed in sucrose-buffered 4% paraformaldehyde, rinsed 
in PBST, dehydrated through an ethanol series, and stored in 100% methanol at -20 oC.  
Whole mount in situ hybridizations were carried out by standard protocol as previously 
described (47).  cDNAs were cloned into the pCR-TOPO-II vector (Invitrogen) and 
riboprobes for the indicated genes were made with digoxigenin-labeled UTP (Roche).   
 
4.3.5 Alcian blue staining 
 
 72 hpf embryos were fixed and dehydrated as above.  Dehydrated embryos were 
bleached in 30% hydrogen peroxide and stained in an Alcian blue solution (1% 
concentrated hydrochloric acid, 70% ethanol, and 0.1% Alcian blue).  Embryos were 
cleared in acidic ethanol. 
 
4.3.6 Western blotting 
 Zebrafish embryos were collected at 72 hpf and placed in an SDS lysis buffer (10 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton-X, 0.1% SDS) and 1x protease inhibitor 
mixture (Sigma).  The embryos were homogenized using the Tissuelyzer II (Qiagen).  
Lysates were quantified using the DC protein assay (Bio-Rad).  Samples were run 
through Tris-glycine 4–12% gradient NuPage gels using the MES buffer (Invitrogen) and 
transferred to PVDF membrane.  Blots were probed using the following primary 
antibodies: rabbit α-H3K27me3 (Millipore), mouse α-H3K27me3 (Abcam), and rabbit α-
H3 (Abcam). 
 Blots were quantified by calculating intensity using Adobe Photoshop for 
H3K27me3 and control (histone H3).  Means and standard deviations were calculated 
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The histone methyltransferase Ezh2 is responsible for the deposition of the 
H3K27me3 mark (18).  It is also a member of the Polycomb group proteins, a group of 
developmental regulators best known for their regulation of hox gene regulation during 
development (6).  As such, it would be compelling to know how Ezh2 affects vertebrate 
development.  However, murine knockouts of Ezh2 are embryonic lethal, and thus we 
have previously not known how loss of Ezh2, and thus the H3K27 trimethyl mark, affects 
development (3).  To answer this question, we opted to use the developing zebrafish as a 
model to study the role of Ezh2 in development and particularly in the differentiation of 
the gut.  We performed whole mount in situ hybridization on uninjected wild type 
embryos to determine the expression pattern of ezh2 in the developing embryo.  Ezh2 is 
ubiquitously expressed as early as 1 hour postfertilization (hpf).  It continues to be so 
through approximately 24 hpf, at which point in time the marker becomes increasingly 
anterior.  By 5 days post fertilization (dpf), ezh2 is found diffusely in the brain of the 
embryo (Figure 4.1). 
In order to better characterize the loss of H3K27 methylation in developing 
zebrafish, morpholino knockdown of ezh2, the H3K27 methyltransferase, was performed.  
RT-PCR of the affected region of ezh2 in ezh2 morpholino injected embryos shows 
decreased splicing of ezh2 pre-mRNA (Figure 4.2).  Embryos injected with control 
morpholino do not show loss of ezh2 pre-mRNA splicing.  Protein extracted from ezh2 
morphants and blotted for H3K27me3 shows decreased levels of H3K27me3 compared 
to control morphant embryos (Figure 4.2).   
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We wanted to further characterize the loss of ezh2 in the developing zebrafish 
embryo.  Brightfield microscopy of embryos grown without PTU injected with ezh2 
morpholino shows that loss of ezh2 delays development at the 24 hpf stage.  At 48 hpf, 
these embryos lack the pigmentation now present in the control morpholino injected 
embryos.  They also retain a curvature of the spine, whereas control morphant embryos 
have completed the straightening of the spine.  By 72 hpf, the ezh2 morphant embryos 
have developed pigmentation, but they display a spectrum of morphological phenotypes 
(Figure 4.2).  While all embryos display a loss of cartilage formation in the jaw and fins, 
a subset of embryos displays an indentation in the head, suggesting abnormalities in brain 
development.  The more severe phenotypes have curvature of the spine and often have a 
shortened body, indicative of spinal malformations, similar to what is observed in PRC1 
knockouts in mice.  At its most severe, ezh2 hypomorphism manifests as extreme 
curvature of the spine, a collapsed jaw, heart edema, and body lengths approximately half 
the size of control-injected embryos. 
 The expression pattern of ezh2 guided our search to determine how partial ezh2 
loss affects development.  Because ezh2 is predominantly expressed in the brain, we 
wanted to determine whether the loss of ezh2 caused brain formation defects.  Whole 
mount in situ hybridization of five early brain markers, stained at 18 and 30 hpf, showed 
no change in ezh2 morphants in four of the markers, with a slight downregulation of 
zash1a when ezh2 is decreased (Figure 4.3).  No signal was lost completely in the ezh2 
morphant. 
 Due to the gross morphological defects caused by deficiency in ezh2 by 72 hpf, 
we wanted to determine whether this deficiency manifested in developmental defects on 
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later developing organ systems.  Whole mount in situ hybridization shows that ezh2 
morphants have normal staining for fabp10, a marker for development of liver, and 
insulin, the marker for endocrine pancreas (Figure 4.4).  Normal staining in these 
markings indicates that while developmental defects exist in the ezh2 morphant, total 
organism development is not delayed.  However, while some markers develop normally, 
whole mount in situ hybridization of myoD, the marker for somite development, is 
affected by ezh2 loss, and alcian blue staining of 72 hpf ezh2 morphants indicates a total 
loss of cartilage formation (Figure 4.4).  These defects can be partially or completely 
rescued by coinjection with ezh2 mRNA (Figure 4.5). 
 We show in Chapter 3 that APC mediates regulation of H3K27me3.  As APC is 
responsible for the differentiation of the zebrafish intestine, we were interested in 
determining whether ezh2 was also involved in this process and whether this affected 
multiple cell types or it was unique to the enterocyte lineage.  While whole mount in situ 
hybridization of gata6, the marker for primordial gut development, was unaffected in 
ezh2 morphant embryos, three markers for differentiated cells in the intestine were 
affected by ezh2 hypomorphism.  Two markers for enterocytes, i-fabp (fixed at 72 hpf) 
and pept1 (fixed at 102 hpf) and a marker for goblet cells, agr2 (fixed at 98 hpf) were 
absent in the ezh2 morphant (Figure 4.4), indicating that ezh2 plays a role in the proper 
differentiation of multiple cell types in the developing intestine.  (The expression of i-




Mouse knockouts of the histone methyltransferase Ezh2 are embryonic lethal, 
corroborating its necessity in early development (3).  Studies have shown that Ezh2 
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coordinates the gene expression during differentiation of stem cells (48), indicating a role 
for Ezh2 in cell fate decisions, and this may explain its necessity during early 
development.  Because of the inability to study Ezh2 loss in the developing mouse, we 
used the developing zebrafish embryo to study ezh2 and how its loss affects early 
development. 
 Whole mount in situ hybridization of ezh2 mRNA shows that ezh2 is expressed 
ubiquitously in the embryo from 1 hpf through 24 hpf.  This ubiquitous expression is 
consistent with the need for ezh2 in early embryonic development.  After 24 hpf, ezh2 
mRNA expression becomes consistently anterior up to 4 dpf, with expression becoming 
diffuse through the brain from 5 dpf and older.  This may suggest that as the embryo ages 
and has more developed organ systems, the need for ezh2 decreases.  This would support 
a role for ezh2 in the development and proper cell fate decisions in organogenesis.  Other 
studies have shown that ezh2 expression is associated with highly proliferative tissue and 
is less needed in more differentiated tissues (49).  This is consistent with ezh2 being 
expressed ubiquitously in the early development of the zebrafish embryo, as cells are 
rapidly dividing to form organ systems and anatomical structures. 
 Morpholino knockdown of ezh2 provided an approximately 50% of knockdown 
of H3K27me3, which was used as a readout for ezh2 activity.  These hypomorphic 
embryos displayed a range of phenotypes, including the lack of cartilage formation in the 
jaw and fins and a curvature of the spine resulting in a “curly tail” phenotype.  The lack 
of cartilage formation is reminiscent of retinoic acid deficient zebrafish (particularly the 
apcmcr zebrafish line) (47).  The tail phenotype seen was reminiscent of the spinal 
malformations that occur in PRC1 knockout mice (31, 50, 51).  Vertebral abnormalities 
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are also common defects seen in hox mutant mouse models (52–54).  Several hox genes 
were transcriptionally misregulated in the ezh2 morphant (data not shown), so these types 
of patterning malformations in the spine provide additional evidence that ezh2 is playing 
a role in the regulation of hox genes in the developing zebrafish.   
 Ezh2 hypomorphism displayed a variety of different phenotypes with regards to 
development and organogenesis.  Although ezh2 is largely expressed in the brain at later 
stages, early brain markers did not show defects, indicating that an incomplete 
knockdown is insufficient to disrupt brain development or that lack of ezh2 can be 
compensated for in early brain development. At the 72 hpf stage, endocrine pancreas and 
liver were also not affected by lack of ezh2.  However, underdeveloped somite formation 
and loss of cartilage formation in the jaw and fins were observed in the ezh2 morphant.  
These results show that hypomorphism of ezh2 does not delay total embryonic 
development.  This is at odds with what is seen in the mouse knockout, but not 
inconsistent with hypomorphism of other chromatin modifiers in developing zebrafish 
(55, 56).  While gradients of these modifiers display tissue specific developmental 
defects, not experiencing a total loss of these factors allows for study in a manner that is 
unavailable in mammalian systems.  Underdeveloped somite formation and loss of 
cartilage development are two phenotypes that are seen in retinoic acid deficient models 
(51, 57, 58).  These results are striking because the ezh2 morphant appears to be retinoic 
deficient, but the data presented in Chapter 3 preclude rescue by treatment with 
exogenous RA.  The results presented in this chapter give additional implications that RA 
is responsible for the regulation of H3K27me3, the mark laid down by ezh2 enzymatic 
activity, but also adds evidence that ezh2 is a downstream effector of retinoic acid 
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signaling.  Both retinoic acid and ezh2 are required for proper development and 
differentiation in certain organ systems. 
While we had previously seen a phenotype in the developing gut similar to apcmcr 
zebrafish, we wanted to further characterize what effect the hypomorphism of ezh2 had 
on the developing intestine.  Primordial gut develops normally in ezh2 morphants, but 
markers for two types of differentiated cells (enterocytes and goblet cells) are absent in 
ezh2 morphants, indicating that loss of ezh2 affects multiple types of differentiated cells.  
This suggests that ezh2 is playing a role at either the stem cell level, affecting the 
transition into transit-amplifying cells, or at the transit-amplifying cell level, causing 
lineage specification, and when ezh2 is lost, these cells are not able to successfully 
complete differentiation.  While these results state that ezh2 is necessary for the 
rudimentary regulation of cell differentiation, this has far reaching implications for the 
misregulation of ezh2 in cancer.  Several cancer types have decreased expression or 
activity of ezh2, and we present a new model wherein the readout of ezh2 activity, 
H3K27me3, is decreased when APC is lost.  The loss of H3K27me3 leads to inability of 
cells to differentiate, which is a hallmark of carcinomas (59, 60).  Treatments that reverse 
this inability to differentiate have the potential to be more effective treatments and would 
be more specific for cancer cells than current therapies. 
 These findings allow for new insights into the role of ezh2 in development.  Of 
particular interest is the tissue specific defects seen, as they open up novel areas of 
research for how ezh2 plays a role in the differentiation, both in development and with 







1. S. H. Orkin, K. Hochedlinger, Chromatin connections to pluripotency and cellular 
reprogramming. Cell 145, 835–850 (2011). 
 
2. W. L. Tam, B. Lim, Genome-wide transcription factor localization and function in 
stem cells. StemBook (Cambridge, Harvard Stem Cell Institute, 2008) 
 
3. D. O’Carroll et al., The Polycomb-group gene Ezh2 is required for early mouse 
development. Mol. Cell. Biol. 21, 4330–4336 (2001). 
 
4.A. H. Peters et al., Loss of the Suv39h histone methyltransferase impairs mammalian 
heterochromatin and genome stability. Cell 107, 323–337 (2001). 
 
5. M. Tachibana et al., G9a histone methyltransferase plays a dominant role in 
euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. 
Genes Dev. 16, 1779–1791 (2002). 
 
6. G. A. Jürgens, A group of genes controlling the spatial expression of the bithorax  
complex in Drosophila. Nature 316, 153–155 (1985). 
 
7. T. R. Breen, I. M. Duncan, Maternal expression of genes that regulate the bithorax 
complex of Drosophila melanogaster. Dev. Biol. 118, 442–456 (1986). 
 
8. G. Struhl, A gene product required for correct initiation of segmental determination in 
Drosophila. Nature 293, 36–41 (1981). 
 
9. M. Mallo, D. M. Wellik, J. Deschampes, Hox genes and regional patterning of the 
vertebrate body plan. Dev. Biol. 344, 7–15 (2010). 
 
10. T. Takeuchi et al., Gene trap capture of a novel mouse gene, jumonji, required for 
neural tube formation. Genes Dev. 9, 1211–1222 (1995). 
 
11. S. Wang et al., Chick Pcl2 regulates the left-right asymmetry by repressing Shh 
expression in Hensen’s node. Development 131, 4381–4391 (2004). 
 
12. F. Forzati et al., CBX7 is a tumor suppressor in mice and humans. J. Clin. Invest. 
122, 612–623 (2012). 
 
13. M. de Napoles et al., Polycomb group proteins Ring1A/B link ubiquitylation of 




14. D. Pasini, A. P. Bracken, M. R. Jensen, E. Lazzerini Denchi, K. Helin, Suz12 is 
essential for mouse development and for EZH2 histone methyltransferase activity. EMBO 
J. 23, 4061–4071 (2004). 
 
15. C. Faust, A. Schumacher, B. Holdener, T. Magnuson, The eed mutation disrupts 
anterior mesoderm production in mice. Development 121, 273–285 (1995). 
 
16. M. K. Pirity, J. Locker, N. Schreiber-Agus, Rybp/DEDAF is required for early 
postimplantation and for central nervous system development. Mol. Cell. Biol. 25, 7193–
7202 (2005). 
 
17. R. Margueron, D. Reinberg, The Polycomb complex PRC2 and its mark in life. 
Nature 469, 343–349 (2011). 
 
18. R. Cao et al., Role of histone H3 lysine 27 methylation in Polycomb-group silencing. 
Science 298, 1039–1043 (2002). 
 
19. 134. J. Min, Y. Zhang, R. M. Xu, Structural basis for specific binding of Polycomb 
chromodomain to histone H3 methylated at Lys 27. Genes Dev 17, 1823–1828 (2003). 
  
20. H. Wang et al., Role of histone H2A ubiquitination in Polycomb silencing. Nature 
431, 873–878 (2004). 
 
21. M. Casanova et al., Polycomblike 2 facilitates the recruitment of PRC2 Polycomb 
group complexes to the inactive X chromosome and to target loci in embryonic stem 
cells. Development 138, 1471–1482 (2011). 
 
22. J. L. Rinn et al., Functional demarcation of active and silent chromatin domains in 
human HOX loci by noncoding RNAs. Cell 129, 1311–1323 (2007). 
 
23.  J. Zhao, B. K. Sun, J. A. Erwin, J. J. Song, J. T. Lee, Polycomb proteins targeted by a 
short repeat RNA to the mouse X chromosome. Science, 332, 750–756 (2008). 
 
24. M. Ku et al., Genomewide analysis of PRC1 and PRC2 occupancy identifies two 
classes of bivalent domains. PLoS Genet. 4, e1000242. (2008). 
 
25. L. A. Boyer et al., Polycomb complexes repress developmental regulators in murine 
embryonic stem cells. Nature 441, 349–353 (2006). 
 
26. R. E. Collins et al., In vitro and in vivo analyses of a Phe/Tyr switch controlling 
84 
 
product specificity of histone lysine methyltransferases. J. Biol. Chem. 280, 5563–5570 
(2005). 
 
27. J.-F- Couture, L. M. A. Dirk, J. S.  Brunzelle, R. L. Houtz, R. C. Trievel, Structural 
origins for the product specificity of SET domain protein methyltransferases. Proc. Natl. 
Acad. Sci. U. S. A. 105, 20659–20664 (2008). 
 
28. S. Kaneko, J. Son, S. S. Shen, D. Reinberg, R. Bonasio, PRC2 binds active promoters 
and contacts nascent RNAs in embryonic stem cells. Nat. Struct. Mol. Biol. 20, 1258–
1264 (2013). 
 
29. C. Davidovich, L. Zheng, K. J. Goodrich, T. R. Cech, Promiscuous RNA binding by 
Polycomb repressive complex. Nat. Struct. Mol. Biol. 20, 1250–1257 (2013). 
 
30. T. Akasaka et al., A role for mel-18, a Polycomb group-related vertebrate gene, 
during the anteroposterior specification of the axial skeleton. Development 122(5), 1513–
1522 (1996). 
 
31. A. Kirmizis, S. M. Bartley, P. J. Farnham, Identification of the Polycomb group 
protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol. Cancer 
Ther. 2, 113–121 (2003).  
 
32. M. Sawa et al., BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. 
Int. J. Hematol. 82, 42–47 (2005). 
 
33. S. Beà et al., BMI-1 gene amplification and overexpression in hematological 
malignancies occur mainly in mantle cell lymphomas. Cancer Res. 61, 2409–2412 
(2001). 
 
34. C. Leung et al., Bmi1 is essential for cerebellar development and is overexpressed in 
human medulloblastomas. Nature 428, 337–341 (2004). 
 
35. K. Nowak et al., BMI1 is a target gene of E2F-1 and is strongly expressed in primary 
neuroblastomas. Nucleic Acids Res. 34, 1745–1754 (2006). 
 
36. F. J. van Kemenade et al., Coexpression of BMI-1 and EZH2 Polycomb-group 
proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin 
lymphoma. Blood 97, 3896–3907 (2001). 
 
37. S. Arisan et al., Increased expression of EZH2, a Polycomb group protein in bladder 
carcinoma. Urol. Int. 75, 252–257 (2005). 
85 
 
38. J. D. Raman et al., Increased expression of the Polycomb group gene, EZH2, in 
transitional cell carcinoma of the bladder. Clin. Cancer Res. 11, 8570–8576 (2005). 
 
39. S. Weikert et al., Expression levels of the EZH2 Polycomb transcriptional repressor 
correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. 
Med. 16, 349–353 (2005). 
 
40. C. G. Kleer et al., EZH2 is a marker of aggressive breast cancer and promotes 
neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 100, 
11606–11611 (2003). 
 
41. I. M. Bachmann et al., EZH2 expression is associated with high proliferation rate and 
aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, 
prostate, and breast. J. Clin. Oncol. 24, 268–273 (2006). 
 
42. F. M. Raaphorst et al., Poorly differentiated breast carcinoma is associated with 
increased expression of the human Polycomb EZH2 gene. Neoplasia 5, 481–488 (2003). 
 
43. K. Collett et al., Expression of enhancer of zeste homologue 2 is significantly 
associated with increased tumor cell proliferation and is a marker of aggressive breast 
cancer. Clin. Cancer Res. 12, 1168–1174 (2006). 
 
44. S. Varambally et al., The Polycomb group protein EZH2 is involved in progression of 
prostate cancer. Nature 419, 624–629 (2002). 
 
45. O. R. Saramämaki et al., The gene for Polycomb group protein enhancer of zest 
homolog 2 (EZH2) is amplified in late-stage prostate cancer. Gene Chromosome Cancer 
45, 639–645 (2006). 
 
46. J. Yu et al., A Polycomb repression signature in metatstatic prostate cancer predicts 
cancer outcome. Cancer Res. 67, 10657–10663 (2007). 
 
47. L. D. Nadauld, I. T. Sandoval, S. Chidester, H. J. Yost, D. A. Jones, Adenomatous 
polyposis coli control of retinoic acid biosynthesis is critical for zebrafish intestinal 
development and differentiation. J. Biol. Chem. 279, 51581–51589 (2004). 
 
48. E. Ezhkova et al., Ezh2 orchestrates gene expression for the stepwise differentiation 
of tissue-specific stem cells. Cell 136, 1122–1135 (2009). 
 
49. R. Margueron et al., Ezh1 and Ezh2 maintain repressive chromatin through different 
86 
 
mechanisms. Mol. Cell 32, 503–518 (2008). 
 
50. N. M. van de Lugt et al., Posterior transformation, neurological abnormalities, and 
severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-
oncogene. Genes Dev. 8, 757–769 (1994). 
 
51. D. Lohnes et al., Function of the retinoic acid receptors (RARs) during development 
(I). Craniofacial and skeletal abnormalities in RAR double mutants. Development 120, 
2723–2748 (1994). 
 
52. C. V. Wright, K. W. Cho, J. Hardwicke, R. H. Collins, E. M. De Robertis, 
Interference with function of a homeobox gene in Xenopus embryos produces 
malformations of the anterior spinal cord. Cell 59, 81–93 (1989). 
 
53. B. G. Condie, M. R. Capecchi, Mice homozygous for a target disruption of Hoxd-3 
(Hox-4.1) exhibit anterior transformations of the first and second cervical vertebrae, the 
atlas and the axis. Development 119, 579–595 (1993). 
 
54. R. Ramírez-Solis, H. Zheng, J. Whiting, R. Krumlauf, A. Bradley, Hoxb-4 (Hox-2.6) 
mutant mice show homeotic transformation of a cervical vertebra and defects in the 
closure of the sternal rudiments. Cell 73(2), 279–294 (1993). 
 
55. E. Li, T. H. Bestor, R. Jaenisch, Targeted mutation of the DNA methyltransferase 
gene results in embryonic lethality. Cell 69, 915–926 (1992). 
 
56. K. Rai et al., Zebra fish Dnmt1 and Suv39h1 regulate organ-specific terminal 
differentiation during development. Mol. Cell. Biol. 26, 7077–7085 (2006). 
 
57. O. Halevy, O. Lerman, Retinoic acid induces adult muscle cell differentiation 
mediated by the retinoic acid receptor-alpha. J. Cell Physiol. 153, 566–572 (1993). 
 
58. T. Ryan et al., Retinoic acid enhances skeletal myogenesis in human embryonic stem 
cells by expanding the premyogenic progenitor population. Stem Cell Rev. 8, 482–493 
(2012). 
 
59. G. B. Pierce, C. Wallace, Differentiation of malignant to benign cells. Cancer Res. 
31, 127–134 (1971). 
 
60. G. B. Pierce, W. C. Speers, Tumors as caricatures of the process of tissue renewal: 














5.1 Summary and Perspectives 
 This dissertation produces new insights into how epigenetics plays a role in the 
differentiation process of the intestine.  In doing so, it further characterizes how retinoic 
acid is able to carry out the daunting task of regulating intestinal differentiation.  The data 
paint a clear picture of two epigenetic marks that deviate when APC is mutated, 
displaying a broader role for APC in the control of epigenetics during the differentiation 
process.  They also introduce a role for the histone methyltransferase Ezh2 in the 
regulation of differentiation in the intestine and describe how partial loss of Ezh2 affects 
the developing animal. 
 This study traces the path of retinoic acid in its role in the developing intestine.  
We show that retinoic acid biosynthesis is controlled through APC by the histone 
demethylase LSD1.  LSD1 is misregulated when APC is absent and aberrantly 
demethylates the promoter of rdh1l, effectively turning off transcription.  This is one of 
many factors that is responsible for the repression of retinoic acid biosynthesis when 
APC is mutated (1, 2), but this adds a direct mechanism by epigenetic repression.  It also 
adds a potential drug target for the treatment of mutated APC syndromes.  We also show 
that retinoic acid controls the levels of H3K27 trimethylation in the developing embryo, 
adding another level of epigenetic regulation under the control of retinoic acid as well as 
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suggesting potential mechanisms for RA-mediated differentiation.  We establish an 
epistatic mechanism whereby retinoic acid, through its regulation of the expression of 
cyclooxygenase-2, regulates H3K27me3.  In this mechanism, unlike what we have 
previously seen with the DNA demethylase components, RA does not control the levels 
of PRC2 transcripts, introducing a novel paradigm whereby RA may control chromatin 
modifiers (Figure 5.1). 
 The roles of APC in the regulation of retinoic acid and intestinal differentiation 
and in the regulation of chromatin modifiers that are involved in this process instruct 
proper cellular differentiation and, when absent, the progression of tumorigenesis.  
Progenitor-like cells contain higher levels of LSD1, lower levels of the RA biosynthetic 
machinery, and lower levels of H3K27me3.  APC drives a transition, through its 
regulation of retinoic acid production and chromatin modifiers, that gives rise to a 
differentiated cell, with higher levels of RA, more H3K27me3 to shut down improper 
signaling pathways, and less LSD1 (Figure 5.1).  When APC is absent, in the case of 
cancer, this transition cannot happen, leaving the cancer cell in a more progenitor-like 
state, which leads to defective cell fating and hyperproliferation.  The chromatin state of 
these cells is of particularly importance.  This work shows that APC mutation leads to a 
more permissive chromatin state, containing less H3K27me3, a hallmark of 
undifferentiated cells.  The inability to regulate H3K27 methylation – and thus the 
multiple pathways required for differentiation that this mark has been shown to occupy – 
highlights the undifferentiated state of a cell harboring an APC mutation. 
 This study also shows that both retinoic acid and Ezh2 are necessary for the 
terminal differentiation of the intestine in developing zebrafish.  Ezh2 plays a role in the 
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regulation of intestinal differentiation, either at the stem cell or transit-amplifying cell 
level, as is shown by the absence of multiple differentiated cell types when Ezh2 is 
knocked down. 
 In addition to its role in the intestine, we show morphological and developmental 
defects of Ezh2 absence in a vertebrate.  A loss of ezh2 leads to a curvature of the spine, 
a phenotype similar to the vertebral defects seen in the loss of PRC1 components in mice 
(3–5), as well as decrease in skeletal muscle formation and loss of cartilage in fin and 
jaw, additional retinoic acid deficient phenotypes (6–8).  Although RA is incapable of 
rescuing the loss of terminal differentiation in the intestine in the ezh2 morphant, it is 
obvious from these phenotypes that retinoic acid plays a role in the regulation of PRC2 in 
the developing intestine, albeit upstream of PRC2. 
 Taken together, these findings not only increase our understanding of how histone 
modifiers plays a role in the regulation of intestinal differentiation and the effects of their 
aberration in cancer, they also highlight the importance of understanding the regulation of 
epigenetic marks and the mechanism by which they are deposited.  While we provide an 
epistatic mechanism for the regulation of H3K27 methylation, it is still unclear how these 
marks are misregulated when APC is mutated.  Such an understanding would open new 
areas of study and provide for potential drug targets in FAP and other mutated APC 
syndromes. 
 
5.2 Future Directions 
 The data presented in this dissertation allow for several interesting new areas of 
study.  While we continue to increase our knowledge of which factors are misregulated 
when APC is mutated, it is still unclear how loss of APC affects each of these factors.  
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We show that LSD1 is aberrantly expressed in conditions of APC mutation, but it is 
unclear why it is misexpressed.  As it acts upstream of retinoic acid loss, it is not 
controlled, as many factors misregulated in APC mutation, by retinoic acid, so APC must 
have additional ways of controlling epigenetic regulators.  We also do not have a clear 
idea of which factors can cause LSD1 to switch substrate preference from methylated 
H3K9 to methylated H3K4.  Future work to examine additional roles of APC in the 
regulation of upstream regulators of RA biosynthesis will shed light on how the 
epigenetic regulators of cellular differentiation are controlled as well as elucidate further 
mechanisms and pathways that cells use to undergo the transition from stem to terminally 
differentiated cell. 
 Of great interest would be the underlying mechanism of how Cox-2 regulates 
H3K27 trimethylation, regarding both the pathways Cox-2 employs to regulate this mark 
and the process through which the effectors of the mark are modified.  We have explored 
theories on both counts, but all have proved inconclusive.  We were unable to determine 
whether localization of H3K27me3 changes in apcmcr zebrafish, a method of regulation 
that has the potential to affect the expression of multiple differentiation pathways.  We 
also explored the effect of multiple prostaglandins, the final products of Cox-2 enzymatic 
activity (9, 10), on H3K27me3, but saw either no effect or an effect inconsistent with 
Cox-2 overexpression.  More exploration with the prostaglandins may prove fruitful in 
determining how H3K27 methylation is misregulated in the absence of APC.  Another 
area of study could include the regulation of Ezh2 by the Akt pathway.  Akt is 
overexpressed in early adenomas when APC is mutated (11).  Ezh2 has been shown to be 
phosphorylated by Akt.  This phosphorylation affects its activity, causing decreases in 
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H3K27 trimethylation (12).  This pathway may be aberrantly activated in cells with APC 
mutation. 
 Further exploration into the roles of ezh2 in development could also prove 
fruitful.  Determining where ezh2 affects differentiation in the intestine (at the stem cell- 
or transit amplifying cell-level) could provide insights into how the pathways governing 
these processes are regulated.  This also has the potential to reveal stem cell markers in 
the intestine, a field currently poorly understood.  Other studies have shown that ezh2 
contains an RNA-binding domain (13).  This is consistent with previous findings that 
PRC2 can be recruited by long noncoding RNAs, but it raises questions as to whether, 
through this domain, Ezh2 can play regulatory roles unrelated to its histone 
methyltransferase activity.  Determining whether catalytic mutants of Ezh2 or RNA-
binding mutants of Ezh2 would be able to rescue the defects seen in the guts of ezh2 
morphants would provide unique perspectives into what Ezh2 is doing in the developing 
intestine.  It could also provide insight into any regulation of intestinal differentiation by 




1. L. D. Nadauld et al., Adenomatous polyposis coli control of C-terminal binding 
protein-1 stability regulates expression of intestinal retinol dehydrogenases. J. Biol. 
Chem. 281, 37828–37835 (2006). 
 
2. K. Rai et al., DNA demethylase activity maintains intestinal cells in an 
undifferentiated state following loss of APC. Cell 142, 930–942 (2010). 
 
3. M. del Mar Lorente et al., Loss- and gain-of-function mutations show a Polycomb 
group function for Ring1A in mice. Development 127(3), 5093–5100 (2000). 
 
4. N. M. van de Lugt et al., Posterior transformation, neurological abnormalities, and 
severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-
oncogene. Genes Dev. 8, 757–769 (1994). 
98 
 
5. T. Akasaka et al., A role for mel-18, a Polycomb group-related vertebrate gene, during 
the anteroposterior specification of the axial skeleton. Development 122(5), 1513–1522 
(1996). 
 
6. O. Halevy, O. Lerman, Retinoic acid induces adult muscle cell differentiation mediated 
by the retinoic acid receptor-alpha. J. Cell Physiol. 153, 566–572 (1993). 
 
7. T. Ryan et al., Retinoic acid enhances skeletal myogenesis in human embryonic stem 
cells by expanding the premyogenic progenitor population. Stem Cell Rev. 8, 482–493 
(2012). 
 
8. D. Lohnes et al., Function of the retinoic acid receptors (RARs) during development 
(I). Craniofacial and skeletal abnormalities in RAR double mutants. Development 120, 
2723–2748 (1994). 
 
9. M. Hemler, W. E. Lands, Purification of the cyclooxygenase that forms prostaglandins. 
Demonstration of two forms of iron in the holoenzyme. J. Biol. Chem. 251, 5575–5579 
(1976). 
 
10. T. Miyamoto, N. Ogino, S. Yamamoto, O. Hayaishi, Purification of prostaglandin 
endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 251, 
2629–2636 (1976). 
 
11. H. K. Roy et al., AKT proto-oncogene overexpression is an early event during 
sporadic colon carcinogenesis. Carcinogenesis 23, 201–205 (2002). 
 
12. T.-L. Cha et al., Akt-mediated phosphorylation of EZH2 suppresses methylation of 
lysine 27 in histone H3. Science 310, 306–310 (2005). 
 
13. J. Zhao, B. K. Sun, J. A. Erwin, J. J. Song, J. T. Lee, Polycomb proteins targeted by a 
short repeat RNA to the mouse X chromosome. Science, 332, 750–756 (2008). 
99
100
